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The TestSmart program is a collaborative
project between the Johns Hopkins Center
for Alternatives to Animal Testing, the
Environmental Defense Fund, Carnegie-
Mellon University, and the University of
Pittsburgh (1). The TestSmart program was
conceived in response to the U.S.
Environmental Protection Agency’s (U.S.
EPA’s) Chemical Right-to-Know Initiative
High Production Volume (HPV) Chemical
Challenge Program with the goal of provid-
ing a humane, economical, and efficient
method of collecting basic toxicologic data
for HPV chemicals (2–4). For this purpose,
HPV chemicals are deﬁned as those produced
or imported into the United States in quanti-
ties greater than 1 million pounds per year.
The program asks chemical producers and
importers to voluntarily provide basic toxico-
logic data on HPV chemicals (5). These
chemicals were identified under the Toxic
Substance Control Act 1990 Inventory
Update Rule (6). Overall, the HPV Chemical
Challenge Program list contains 2,800 chemi-
cals (7). The Screening Information Data Set
(SIDS) of the Organization for Economic
Cooperation and Development was selected
as the toxicologic criteria needed to meet the
goals of the HPV Chemical Challenge
Program (8). SIDS includes tests for genotox-
icity, acute and chronic toxicity, reproductive
toxicity, ecotoxicity, and environmental fate.
One of the challenges, as part of the
TestSmart Program, was to assess the overall
magnitude of the health hazards posed by
HPV chemicals based on structure–activity
relationship (SAR) modeling. The U.S. EPA
will consider test result submission for the
HPV Program based on SAR models that are
scientiﬁcally justiﬁable (9). As part of this pro-
gram we undertook an analysis of a random
set of 200 HPV chemicals and predicted the
probability of each to induce a variety of toxic
effects including genotoxicity, carcinogenic-
ity, developmental toxicity, and systemic 
toxicity. The majority of these chemicals are
not part of the learning sets used to derive the
SAR models, thereby eliminating the possibil-
ity of tautological artifacts. Although SAR
projections may not have perfect predictivity,
the current study seeks to assess the preva-
lence of toxicants among HPV chemicals.
Such estimates based on SAR techniques can
be derived for populations of molecules pro-
vided the SAR model has been validated and
its predictivity is known (10–12).
Materials and Methods
HPV chemical selection. A sample of 200
chemicals was selected from among the HPV
chemicals (7). The chemicals chosen were
randomly selected and a) were pure and
unique substances; b) were organic; c) were
nonpolymeric; and d) did not contain metals.
Reference chemicals. A reference set of
10,000 chemicals representing the universe
of chemicals was used as a control set. The
composition of this set is consistent with esti-
mates produced by the National Academy of
Science (13). This set was derived through
sampling chemical structure libraries and the
National Institutes of Health Developmental
Therapeutics Program. This reference set was
used to assess whether the HPV chemicals
represent a greater or lesser toxicologic risk
than other chemicals. For this evaluation we
compared the percentage of chemicals pre-
dicted to be toxic in the HPV sample to the
percentage of chemicals predicted to be toxic
in the reference chemical set.
SAR predictions. We used the CASE/
MULTICASE program (MULTICASE Inc.,
Beachwood, OH) (14–16) to predict the
toxicity of the sampled HPV chemicals and
the 10,000 chemicals in the reference set. All
chemicals from both groups were predicted
for their ability to induce a number of differ-
ent toxic end points (Table 1). Each toxic
end point was predicted separately. The 
predictions are based on the occurrence of
identiﬁed molecular features that have been
previously identified as significantly related
to toxicity for each end point. 
The CASE modeling process begins with
the compilation of a set of chemical structures
(typically in Smiles code) and an experimen-
tally derived biological activity value. These
data are placed into a learning set for the pro-
gram. Each chemical in the learning set is
broken down, in silico, to all possible frag-
ments from 2 to 10 heavy (i.e., nonhydrogen)
atoms. Each fragment is labeled with the
name and activity of its parent chemical.
Upon completion of this process, the pro-
gram organizes the list of fragments and tabu-
lates the number of chemicals containing each
of them. The program then identiﬁes those
fragments that were identiﬁed predominantly
in active chemicals and refers to these frag-
ments as biophores. The selection of bio-
phores is based on the binary experimental
results of each chemical. For example, bio-
phores for a cancer causation model are iden-
tified that are predominantly found in
chemicals that tested positive for carcino-
genicity compared to those that were noncar-
cinogenic. The particular potency value
associated with each biophore is then deter-
mined from the experimental potencies for
the chemicals making up the biophore. The
total list of biophores is then used to derive a
global quantitative SAR (QSAR) equation.
These biophores serve as the basis for both
predictive and mechanistic analysis of toxicity. 
The MULTICASE module then selects
from the list of biophores the most important
one based on its occurrence in the largest
number of chemicals in the learning set. At
this point in the MULTICASE routine, a
congeneric series of chemicals has been identi-
ﬁed, with the biophore being the unifying fea-
ture. MULTICASE then performs a series of
deﬁned chemical substitutions of the atoms in
the first biophore (e.g., one halogen for
another halogen or a nitrogen for a carbon in
aromatic systems) and then searches for these
expanded deﬁnitions of the biophore in the
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fragments. All chemicals containing the bio-
phore and the expanded definitions are
grouped together. Thus a biophore may con-
sist of a single feature or a family of chemi-
cally similar features.
Using the molecules contained in this
family of chemicals as a new learning set,
MULTICASE identiﬁes modulators of their
activity. These modulators may be chemical,
physicochemical, or quantum mechanical
parameters. Modulators augment or decrease
the activity of the chemicals containing the
biophore. Some values and coefficients are
localized to particular atoms of a chemical
(e.g., a charge or highest occupied molecular
orbit coefficient on an individual atom
derived by a modiﬁed Hückel method). The
biophore and identiﬁed modulators are then
used to derive local QSAR equations for
chemicals within this subset. If the entire
learning set is congeneric, then the single
biophore and associated modulators may
explain the activity of the entire set; this usu-
ally does not occur and there will be a group
of molecules not explained by the single bio-
phore and associated modulators. When this
happens, the program will remove from con-
sideration the molecules already explained
and will search for the next biophore. The
process is iterated until all of the active mole-
cules in the learning set have been explained
or until no significant fragments can be
found to explain them.
The resulting list of biophores can then
be used in mechanistic studies or to predict
the activity of yet untested molecules (10).
For example, upon submission for evaluation,
MULTICASE will determine if an unknown
molecule contains a biophore. If the molecule
does not contain a biophore, it will be pre-
dicted, by default, to be inactive. When the
molecule contains a biophore, the program
will make a qualitative prediction that the
chemical is biologically active with an associ-
ated probability that this prediction is correct.
Moreover, MULTICASE will inspect the
molecule for the presence of modulators asso-
ciated with this biophore. The program then
incorporates the parameters for the identiﬁed
modulators into the QSAR equation and pro-
duces a quantitative prediction for the potency
of the chemical. In essence, although bio-
phores are the determining structures, the
modulators will determine whether and to
what extent the biological potential of the
chemical containing the biophore is expressed.
Application of the CASE and MULTI-
CASE programs results in four submodels
(17,18). These are two models to estimate
potency and two to estimate probability of
activity. Because each of them may reflect
different facets of the toxicologic phenom-
ena under study, they are combined to give
an overall Bayesian probability of the toxic-
ity for each chemical tested. A chemical is
considered active if its Bayesian probability
is > 0.6 and negative if it is < 0.4. 
SAR models. A number of validated and
characterized SAR models (11) of toxicologic
phenomena were used in the course of these
studies. These included the induction of
mutations in Salmonella. That database was
developed under the aegis of the U.S. National
Toxicology Program (NTP) (19–23). SAR
models based on subsets of that database have
been described (24–26). SAR models of the
ability to induce error-prone DNA repair in
Escherichia coli (SOS Chromotest; EBPI,
Brampton, Ontario, Canada) (27,28), muta-
tions in cultured mouse lymphoma cells (29),
sister chromatid exchanges (SCEs), chromo-
somal aberrations in cultured Chinese ham-
ster ovary (CHO) cells (30), and unscheduled
DNA synthesis in primary rat hepatocytes
(31) have been described previously, as have
models of the potentials for inducing SCEs
(32) and micronuclei in vivo (33).
We used two rodent carcinogenicity data-
bases: the Carcinogenic Potency Database
(CPDB) assembled by Gold and associates
(34–38); and the rodent carcinogenicity
database generated under the auspices of the
NTP (39,40). SAR models of these databases
have also been described (41–43). We com-
bined the individual projections derived
from these different databases using Bayes’
theorem, described previously (17,18) to
yield a single prediction of carcinogenicity. 
The SAR model of cellular toxicity was
based on assays using cultured BALB/c-3T3
cells (44). A chemical was considered cyto-
toxic if its IC50 (concentration that inhibits
50% growth) value was ≤ 1 µM. The SAR
model of lethality to minnows was derived
from previously published data (45). The
SAR model for lethality to rats (LD50; 50%
lethal dose) was based on data on 1,411
orally administered chemicals extracted from
the Registry of Toxic Effects of Chemical
Substances (46). In that SAR model, toxicity
was deﬁned as LD50 ≤ 7.2 mmol/kg.
The SAR models for eye irritation (47),
sensory irritation (48), developmental toxic-
ity in humans (49) and in hamsters (50),
allergic contact dermatitis (51), inhibition of
gap junctional intercellular communication
(GJIC) (52), and environmental biodegrada-
tion (53) were also used.
The SAR model of α 2u-globulin
nephropathy in male rats (54) was based on
data kindly supplied by L.D. Lehman-
McKeenan from the Procter and Gamble
Company (Cincinnati, OH). 
The predictive ability of each model was
estimated by its ability to correctly predict
the activity of chemicals not used to build the
model but for which we knew the true exper-
imental results. These values are listed in
Table 1 as concordance (i.e., percent correct
predictions over total predictions). These val-
ues were calculated based on pooling multi-
ple 10-fold cross-validation results. Each
learning set was divided 10 times into learn-
ing and validation sets. Each learning set was
used to derive a model, and this model was
then used to predict the activity of the chem-
icals left out in the validation set. Because the
activity of the chemicals in the validation set
was known, we could determine the number
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Table 1. Predicted prevalences of toxicants among groups of chemicals.
Prevalence (%)
Universe of Concordance
SAR model HPV chemical chemicals p-Value (%)
Mutagenicity: Salmonella 19.5 31.5 0.0001 85
SOS DNA repair (Chromotest) 3.0 12.4 < 0.0001 87
Mutagenicity: mouse lymphoma 19.0 49.2 < 0.00001 70
Unscheduled DNA synthesis 6.0 21.8 < 0.00001 78
Sister chromatid exchanges in vitro 29.0 17.1 < 0.00001 71
Chromosomal aberrations in vitro 19.5 33.4 < 0.00001 66
Induction of micronuclei in vivo 46.5 59.5 0.00001 81
Sister chromatid exchanges in vivo 45.5 56.8 0.0007 83
Carcinogenicity in rodents 16.5 33.5 < 0.00001 74
In vivo genotoxicants 8.0 23.0 < 0.00001 NA
Genotoxic carcinogens 4.5 16.0 < 0.00001 NA
Cell toxicity 26.5 41.2 < 0.00001 84
α 2u-Globulin mediated nephropathy 8.5 14.4 0.009 83
Inhibition GJIC 14.0 27.3 < 0.00001 70
Developmental toxicity: hamsters 18.0 26.3 0.004 74
Developmental toxicity: humans 3.0 16.4 < 0.00001 75
Allergic contact dermatitis 31.0 48.4 < 0.00001 86
Sensory irritation 19.5 43.4 < 0.00001 79
Eye irritation 33.0 47.4 0.00003 80
Lethality to rats 15.0 84.7 < 0.00001 84
Toxicity to minnows 38.0 56.4 < 0.00001 76
Biodegradability 47.0 48.1 0.4 70
Abbreviations: GJIC, gap junctional intercellular communication; NA, not applicable because these are joint probabilities
based on two SAR models (11).of correct predictions and estimate the con-
cordance for each model. 
Results and Discussion
The HPV chemicals can be considered to pre-
sent an elevated toxicologic risk to humans
and to the environment based solely on their
large production volume and the consequent
potential for exposure (55). However, it would
be of interest to know whether the HPV
chemicals, as a group, are more or less toxic
than “average” chemicals. To assess this, we
compared the proportion of chemicals in the
HPV sample predicted to be toxic to the pro-
portion of chemicals predicted to be toxic in
the reference set representing the universe of
chemicals. These comparisons were done one
toxic end point at a time. Unexpectedly, for all
toxic effects assessed except one (the in vitro
induction of SCEs), the proportion of chemi-
cals predicted to be toxic among the HPV
sample was signiﬁcantly less than the propor-
tion of chemicals predicted to be toxic in the
reference set (Table 1). The question obvi-
ously arises as to the reason for this decrease in
the number of potentially toxic HPV chemi-
cals when compared to what would be
expected from a random sample of chemicals.
This is particularly relevant given that the
underlying reason for the HPV Challenge pro-
gram is that little is known about the toxicities
of the HPV chemicals (55). From this reason-
ing, it can be assumed that hazardous chemi-
cals were not excluded from production based
on the results of toxicologic prescreens.
A more detailed analysis of the muta-
genic/genotoxic potentials indicate that with
respect to the possibility for inducing muta-
tions in Salmonella, the proportion of HPV
chemicals predicted to be mutagens was signif-
icantly less than that for the reference set
(19.5% vs. 31.5%, p = 0.0001; Table 1).
Interestingly, it has recently been reported that
of 46 HPV chemicals tested for Salmonella
mutagenicity, 20% were mutagens (56).
Moreover, this same report showed an increase
in the proportion of mutagens when compar-
ing HPV chemicals to all chemicals in com-
merce. This is in concordance with our
predictions.
Predictions based on other assays designed
to assess mutagenic and genotoxic activity in
prokaryotes or cultured cells (Table 1)
showed the same pattern; (i.e., the propor-
tion of HPV chemicals predicted to induce
these effects was lower that for the chemicals
in the reference set). The only exception to
this is the proportion of chemicals predicted
to induce SCEs in cultured CHO cells.
However, the ability to induce SCEs in vitro
is not restricted to genotoxicants and may, in
fact, reﬂect cell toxicity (57).
The Salmonella mutagenicity assay is usu-
ally the ﬁrst screen used, but the results are
frequently confirmed by an in vivo test for
genotoxicity. The assay frequently used to
confirm that in vitro assay is the mouse
micronucleus assay (58). The proportion of
chemicals predicted as in vivo micronucleus
inducers among the HPV sample is also signif-
icantly less than that for the reference set
(Table 1). The same is true for the other in
vivo assay, the induction of SCEs in mice
(Table 1). It should be noted that although
the micronucleus assay is conﬁrmatory when
the Salmonella assay indicates the potential for
mutagenicity, the micronucleus assay response
can also be elicited by nongenotoxicants such
as inhibitors of tubulin polymerization and of
microtubular integrity, as well as by aneugens
(59,60). This may explain the greater pro-
jected proportion of micronuclei inducers
when compared to Salmonella mutagens.
Based on predicted positive responses in
both the Salmonella mutagenicity and the
micronucleus assays, which define in vivo
genotoxicants, we estimate that 8% of the
chemicals in the HPV sample possess that
potential, in contrast to 23% of chemicals
in the reference set (Table 1), thus further
suggesting that the HPV chemicals, as a
group, represent less of a genotoxic risk than
chemicals at large.
The major function of many mutagenic-
ity and genotoxicity assays is to help identify
carcinogens that may pose a risk to humans
(58). Based on predictions made by several
SAR models derived from rodent carcino-
genicity data, the HPV sample is estimated to
be significantly less likely to induce cancers
than the reference chemicals (16.5% vs.
33.5%, p < 0.00001; Table 1). However,
these proportions are based on rodent cancer
bioassays in which animals are exposed up to
the maximum tolerated dose for their life-
time. It is doubtful that this is an apt model
for human exposure. On the other hand, the
majority of recognized human carcinogens
are also mutagenic and/or genotoxic (61–63).
To evaluate the prevalence of genotoxic car-
cinogens (39), we predicted the proportion
of chemicals that would induce cancers in
rodents and mutagenicity in Salmonella (i.e.,
genotoxic carcinogens). Again, there was a
significant decrease in the proportion of
chemicals predicted for these end points
between the HPV sample and the reference
set (4.5% vs. 16%, p < 0.00001; Table 1).
Carcinogenicity in rodents is not solely
due to DNA damage. Other mechanisms
including cell toxicity, mitogenesis, and inhi-
bition of GJIC have been postulated (64–71).
For these end points also, the proportion of
chemicals predicted positive in the HPV sam-
ple was less than that of the reference set (e.g.,
cell toxicity, 26.5% vs. 41.2%; α 2u-globu-
lin–mediated nephropathy leading to renal
tumors in male rats, 8.5% vs. 14.4%; and
inhibition of GJIC, 14% vs. 27.3%; Table 1).
The HPV sample is predicted to have a
lower proportion of chemicals that are devel-
opmental toxicants for hamsters or humans
(Table 1). That sample was also predicted to
have a lower proportion of inducers of aller-
gic contact dermatitis, sensory irritation, and
eye irritation (Table 1). Finally, the HPV
sample was predicted to have a much lower
proportion of systemic toxicants than the
reference set (Table 1).
With respect to environmental effects,
the HPV sample was predicted to contain
signiﬁcantly fewer aquatic toxicants than the
reference set (Table 1). However, the esti-
mated environmental biodegradability of the
two groups was not signiﬁcantly different. 
Conclusion
In this study we predicted the occurrence of
chemicals capable of inducing 10 separate
toxicologic end points in a sample of HPV
chemicals and compared these values to those
from a reference set of 10,000 chemicals.
Regardless of the nature of the toxicologic
phenomenon, the subset of HPV chemicals
was estimated to contain a signiﬁcantly lower
proportion of toxicants than the reference set. 
Although it can be expected that the
potential for human contact with the HPV
chemicals is great, the potential for individual
members of the group to induce health effects
is less than expected. The reason for this lower
proportion of toxicants in the HPV sample
and presumably in the entire HPV list is
unknown. However, it may reﬂect chemical
properties of this group that allow them to be
used as chemical stocks. These would include
greater stability and lower reactivity, two use-
ful properties for storage and transport of
chemicals. Thus the HPV chemicals, for util-
ity and handling ease, are not typically reac-
tive. Presumably these chemicals, during the
processing to ﬁnal products, are transformed
into multiple reactive intermediates in less
than HPV quantities.
During the course of this study, Zeiger
and Margolin (56) estimated the proportion
of mutagens in a subset of HPV chemicals
using preexisting data. Their results matched
ours, leading us to conclude that our sample
of HPV chemicals is representative of the
group and that our predictions are in accord
with experimental results. 
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